[HTML][HTML] Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19

…, K Psachoulia, A Sharbaugh, K Streicher… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

…, K Ren, R Roque, K Rosenthal, K Streicher… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …

…, GCKW Koh, KW Padilla, K Streicher… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …

Mammary gland immunity and mastitis susceptibility

LM Sordillo, KL Streicher - Journal of mammary gland biology and …, 2002 - Springer
Lactation is considered the final phase of the mammalian reproductive cycle, and the mammary
gland provides milk for nourishment and disease resistance to the newborn. However, …

[HTML][HTML] IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE

…, S Hasni, R Siegel, M Sanjuan, K Streicher… - Nature …, 2018 - nature.com
Although the aetiology of systemic lupus erythematosus (SLE) is unclear, dysregulated B
cell responses have been implicated. Here we show that an unusual CD11c hi T-bet + B cell …

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

…, S Korn, D She, RD May, K Streicher… - The Lancet …, 2015 - thelancet.com
Background Interleukin 13 is a central mediator of asthma. Tralokinumab is a human
interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two …

Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with …

BW Higgs, CA Morehouse, K Streicher… - Clinical Cancer …, 2018 - AACR
Purpose: To identify a predictive biomarker for durvalumab, an anti–programmed death
ligand 1 (PD-L1) mAb. Experimental Design: RNA sequencing of 97 advanced-stage non–small …

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III …

…, KC Kalunian, RN Kalyani, K Streicher… - Annals of the …, 2022 - ard.bmj.com
Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and …

[HTML][HTML] Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer

…, V Oganesyan, H Fu, Y Niu, W Zhang, K Streicher… - PLoS …, 2016 - journals.plos.org
Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing
studies performed on limited number of samples have revealed potential disease-driving …

Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies

RW Georgantas, K Streicher… - Arthritis & …, 2014 - Wiley Online Library
Objective The molecular basis of inflammatory myopathies such as dermatomyositis (DM),
polymyositis, and inclusion body myositis, which share the characteristics of chronic muscle …